Shares of BriteSmile (BSML:Nasdaq) were among the best-performing health-related stocks Monday, climbing 17% after the seller of teeth-whitening technology said its board rejected an unsolicited buyout offer by privately held Futuredontics. The unsolicited offer, which was first disclosed on June 9, was rejected "because Futuredontics had advised BriteSmile that it does not have the funds required to complete the transaction," BriteSmile said. BriteSmile also said that the formal offer, which was dated June 5, was not appealing to a majority of its own shareholders. Had the deal, which was valued at $4 a share, gone through, BriteSmile shareholders would have received $2 a share in cash and $2 in Futuredontics stock for each share of BriteSmile that they owned. Shares of BriteSmile were trading up 36 cents to $2.25. Shares of Pozen (POZN:Nasdaq) , which were hammered Friday after the company said the Food and Drug Administration requested additional safety information on its migraine headache treatment, bounced back somewhat on Monday after analysts defended the stock. An analyst at HSBC Global Research raised his stock rating to overweight from neutral, saying that the shares represent a high-risk opportunity. The firm, however, did lower its price target on the stock to $11.50 from $15.50, reflecting a delay in the launch of Trexima. Meanwhile, Jefferies & Co. analyst Eun K. Yang, who has a buy rating on the stock, said Pozen's current valuation assumes an about 10% probability for Trexima's eventual success, with a lengthy delay. "As we don't know the exact nature of the requested safety information at present, incremental positive news events will likely provide upside from current levels," Yang wrote in a research note to clients. Still, as a result of the launch delay, the firm lowered its price target on the stock to $15 from $25. Yang now believes that Trexima will reach the market in early 2008. Shares of Pozen recently were up 57 cents, or 10%, to $6.09. Shares of Enzo Biochem (ENZ:NYSE) fell 3% after the biotech company posted a wider third-quarter loss. For the period ended April 30, the company recorded a loss of $3.4 million, or 11 cents a share, on revenue of $9.6 million. During the year-earlier quarter, the company reported a smaller loss of $1.5 million, or 5 cents a share, on revenue of $11 million. "While we continue to make progress at Enzo Therapeutics and in the growth of our intellectual property base, price competition and continuing litigation expenses impacted operating results during the third quarter," the company said. Shares were down 35 cents to $9.73. NPS Pharmaceuticals (NPSP:Nasdaq) shares tumbled 15% after the biotech company laid out plans to slash 53% of its workforce. The company said the cuts would reduce cash burn to about $135 million to $145 million during 2006. By the end of 2006, the company expects to have about two years' worth of cash on hand, or about $114 million to $124 million. "We are taking these measures to reduce operating expenses and preserve cash so we can pursue projects with the highest potential returns and build a stronger and healthier company," NPS said. As part of the restructuring, the company will discontinue all current commercialization efforts in the U.S. for the launch of Preos; close a technical operations facility in Canada; eliminate commercial sales and related field operations; end its agreement with Allergan (AGN:NYSE) to promote Restasis Opthalmic Emulsion to rheumatologists; and sublease about 50% of its Salt Lake City facility. Shares were trading down 83 cents to $4.75. Other health care volume movers included Pfizer (PFE:NYSE) , down 3 cents to $23.50; Amgen (AMGN:Nasdaq) , down 16 cents to $67.48; Elan (ELN:NYSE ADR) , down 31 cents to $15.66; Johnson & Johnson (JNJ:NYSE) , up 14 cents to $61.52; Merck (MRK:NYSE) , up 10 cents to $33.91; Boston Scientific (BSX:NYSE) , down 21 cents to $19.50; Genentech (DNA:NYSE) , up $1.30 to $79.81; UnitedHealth Group (UNH:NYSE) , down 12 cents to $45.65; and Bristol-Myers Squibb (BMY:NYSE) , down 23 cents to $24.72.